Bioverativ Inc (NASDAQ:BIVV) had its price target increased by investment analysts at Stifel Nicolaus to $57.00 in a research report issued on Monday. Stifel Nicolaus’ price objective would indicate a potential upside of 13.32% from the stock’s current price.
Other equities research analysts also recently issued research reports about the company. Gabelli reiterated a “buy” rating on shares of Bioverativ in a research report on Thursday, February 2nd. Goldman Sachs Group Inc started coverage on Bioverativ in a research report on Friday, January 27th. They set a “buy” rating and a $55.00 price objective for the company. Jefferies Group LLC reiterated a “buy” rating and set a $53.00 price objective on shares of Bioverativ in a research report on Wednesday, February 1st. Cowen and Company reiterated a “market perform” rating and set a $47.00 price objective on shares of Bioverativ in a research report on Wednesday, February 8th. Finally, Piper Jaffray Companies started coverage on Bioverativ in a research report on Monday, February 6th. They set a “neutral” rating and a $44.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Bioverativ presently has a consensus rating of “Buy” and an average target price of $53.60.
Shares of Bioverativ (NASDAQ:BIVV) opened at 50.30 on Monday. Bioverativ has a 52-week low of $40.00 and a 52-week high of $54.20. The firm’s 50-day moving average price is $48.89 and its 200-day moving average price is $48.78.
TRADEMARK VIOLATION NOTICE: “Stifel Nicolaus Raises Bioverativ Inc (BIVV) Price Target to $57.00” was originally reported by Mideast Time and is the property of of Mideast Time. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.mideasttime.com/stifel-nicolaus-raises-bioverativ-inc-bivv-price-target-to-57-00/1589147.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.